MIAMI — October 5, 2026
Summit Therapeutics Inc. announced the successful closing of a $2.0 billion strategic equity investment from AstraZeneca, providing capital to accelerate development of ivonescimab, an investigational PD-1/VEGF bispecific antibody. AstraZeneca purchased approximately 108,955 shares of preferred stock, convertible into Summit common stock at a 1:1,000 ratio, representing an effective common-stock price of $18.36 per share. The investment strengthens the strategic relationship between the companies and provides Summit with additional resources to advance ivonescimab across multiple solid-tumor indications.
Ivonescimab Advances as Potential PD-1/VEGF Bispecific
Ivonescimab is designed to combine PD-1 immune checkpoint blockade with VEGF inhibition in a single bispecific antibody. The molecule features a tetravalent structure and cooperative binding intended to increase target engagement in the tumor microenvironment, where PD-1 and VEGF may be expressed at higher levels than in normal tissues. Summit is developing ivonescimab across several solid tumors, including non-small cell lung cancer (NSCLC), colorectal cancer, urothelial carcinoma and head and neck squamous cell carcinoma. The program has also generated positive Phase 3 data in several studies conducted by Summit and Akeso, the molecule’s original developer.
$2 Billion Investment Supports Broad Clinical Development
The new capital will support accelerated development of ivonescimab across multiple clinical programs and combination strategies. Summit is evaluating the candidate in combination with chemotherapy, antibody-drug conjugates and other immunotherapies. Current programs include HARMONi, HARMONi-3 and HARMONi-7 in NSCLC, HARMONi-GI3 in colorectal cancer and HARMONi-GU1 in urothelial carcinoma. Summit is also supporting the ILLUMINE Phase 3 study in recurrent or metastatic head and neck squamous cell carcinoma. The company plans to explore combinations with ADCs including sonesitatug vedotin and datopotamab deruxtecan, expanding the potential applications of ivonescimab across solid tumors.
Advertisement
Summit Builds Toward Regulatory and Commercial Milestones
Ivonescimab is already being evaluated in a broad Phase 3 development program, with Summit pursuing regulatory milestones in the United States. The FDA accepted Summit’s BLA for ivonescimab in previously treated EGFR-mutated NSCLC following positive HARMONi data, with a PDUFA target action date of November 14, 2026. Five Phase 3 studies of ivonescimab have reported positive results to date, including studies in NSCLC and biliary tract cancer. Ivonescimab remains investigational in Summit’s licensed territories, including the United States and Europe, although it received marketing authorization in China in May 2024. The completed $2 billion AstraZeneca investment provides Summit with substantial additional capital as it advances ivonescimab through its expanding clinical and regulatory program and evaluates the candidate across a growing range of solid-tumor settings.
Source: Summit Therapeutics, press release
